Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN)

Legend Biotech Corporation (NASDAQ:LEGN) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On December 17, Cantor Fitzgerald maintained its Overweight rating on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $74. The firm said the stock has come under pressure because of concerns about competition, even though the company’s cancer therapy, Carvykti, is still on track to grow around 100% year-over-year to reach nearly $2 billion in sales in 2025. Legend Biote ...